Table 1 Baseline characteristics of patients in the trials included in the meta-analysis
Study | Country | Treatment regimen | No. of patients | Male/female | Age(mean ± SD, year) | Duration of follow-up (month) | K-L criteria (2/3/4) |
|---|---|---|---|---|---|---|---|
Emadedin [27] | Iran | 40 × 106 MSCs | 19 | 12/7 | 51.7 ± 9.2 | 3,6 | 2/13/4 |
|  |  | Placebo | 24 | 15/9 | 54.7 ± 5.3 | 3,6 | 1/20/3 |
Lamo-Espinosa [28] | Spain | 10 × 106 MSCs | 10 | 4/6 | 65.9(59.5, 70.6) | 6,12 | 1/2/7 |
|  |  | 100 × 106 MSCs | 10 | 8/2 | 57.8(55.0, 60.8) | 6,12 | 3/3/4 |
| Â | Â | HA | 10 | 7/3 | 60.3(55.1, 61.1) | 6,12 | 4/2/4 |
Gupta [29] | India | 25 × 106 MSCs | 15 | NR | 40–70 | 3,6,12 | NR |
|  |  | 50 × 106 MSCs | 15 | NR | 40–70 | 3,6,12 | NR |
|  |  | 75 × 106 MSCs | 15 | NR | 40–70 | 3,6,12 | NR |
|  |  | 150 × 106 MSCs | 15 | NR | 40–70 | 3,6,12 | NR |
|  |  | Placebo | 15 | NR | 40–70 | 3,6,12 | NR |
Vega [30] | Spain | 40 × 106 MSCs | 15 | 7/8 | 57 ± 9 | 12 | NR |
|  |  | HA | 15 | 6/9 | 57 ± 9 | 12 | NR |
Varma [31] | India | MSCs | 25 | NR | 48.2 ± 5.13 | 3,6 | NR |
|  |  | Arthroscopic debridement | 25 | NR | 50.67 ± 5.38 | 3,6 | NR |
Saw [32] | USA | MSCs+HA | 25 | 10/15 | 38 ± 7.33 | 6,12,18 | NR |
|  |  | HA | 25 | 8/17 | 42 ± 5.91 | 6,12,18 | NR |
Vangsness [33] | USA | 50 × 106 MSCs | 18 | 13/5 | 46 | 6,12,24 | NR |
|  |  | 150 × 106 MSCs | 18 | 13/5 | 46 | 6,12,24 | NR |
| Â | Â | HA | 19 | 13/6 | 46 | 6,12,24 | NR |
Wong [34] | Singapore | MSCs+ high tibial osteotomy | 28 | 15/13 | 53(36–54) | 6,12,18,24 | NR |
|  |  | High tibial osteotomy | 28 | 14/14 | 49(24–54) | 6,12,18,24 | NR |
Ha [35] | China | 5 × 106 MSCs | 44 | 14/30 | 55.6 ± 3.6 | 3,6,12 | 10/14/20 |
|  |  | HA | 43 | 12/31 | 57 ± 3.2 | 3,6,12 | 11/11/21 |